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Abstract
OBJECTIVES—Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated 
with a reduced risk of esophageal adenocarcinoma. Epidemiological studies examining the 
association between NSAID use and the risk of the precursor lesion, Barrett's esophagus, have 
been inconclusive.
METHODS—We analyzed pooled individual-level participant data from six case-control studies 
of Barrett's esophagus in the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). 
We compared medication use from 1474 patients with Barrett's esophagus separately with two 
control groups: 2256 population-based controls and 2018 gastroesophageal reflux disease (GERD) 
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controls. Study-specific odds ratios (OR) and 95% confidence intervals (CI) were estimated using 
multivariable logistic regression models and were combined using a random effects meta-analytic 
model.
RESULTS—Regular (at least once weekly) use of any NSAIDs was not associated with the risk 
of Barrett's esophagus (vs. population-based controls, adjusted OR = 1.00, 95% CI = 0.76–1.32; 
I2=61%; vs. GERD controls, adjusted OR = 0.99, 95% CI = 0.82–1.19; I2=19%). Similar null 
findings were observed among individuals who took aspirin or non-aspirin NSAIDs. We also 
found no association with highest levels of frequency (at least daily use) and duration (≥5 years) of 
NSAID use. There was evidence of moderate between-study heterogeneity; however, associations 
with NSAID use remained non-significant in “leave-one-out” sensitivity analyses.
CONCLUSIONS—Use of NSAIDs was not associated with the risk of Barrett's esophagus. The 
previously reported inverse association between NSAID use and esophageal adenocarcinoma may 
be through reducing the risk of neoplastic progression in patients with Barrett's esophagus.
INTRODUCTION
The incidence of esophageal adenocarcinoma has increased more than eightfold in the 
United States in recent decades (1), and the incidence continues to rise (2). Esophageal 
adenocarcinoma is a highly fatal cancer with a five-year survival rate of < 20% (3). Thus, as 
with other aggressive cancers, there is strong interest in identifying chemopreventive agents 
that might help reduce the burden of esophageal adenocarcinoma, such as nonsteroidal anti-
inflammatory drugs (NSAIDs), statins, or acid suppressant medications.
NSAIDs have been shown in experimental studies to have a chemopreventive effect on the 
development of esophageal adenocarcinoma, presumably by blocking cyclooxygenase 
(COX) isoenzymes (aspirin is an inhibitor of COX-1, while other NSAIDs block both 
COX-1 and COX-2) and the production of prostaglandin. In addition, epidemiological 
studies have found a strong inverse association between use of NSAIDs and the risk of 
esophageal adenocarcinoma. In a pooled analysis of data from the Barrett's and Esophageal 
Adenocarcinoma Consortium (BEACON; http://beacon.tlvnet.org/), Liao et al. (4) showed 
that patients who used any NSAIDs had a 32% reduced risk of esophageal adenocarcinoma 
(summary adjusted odds ratio [OR] = 0.68, 95% confidence interval [CI] = 0.56–0.83; 
I2=17%).
Barrett's esophagus is the only known precursor for esophageal adenocarcinoma and may 
affect 2% of the general adult population (5). Compared to the general population, patients 
with Barrett's esophagus have 10- to 55-fold increased risk of developing esophageal 
adenocarcinoma (6-11). Assessment of risk factors for Barrett's esophagus may allow for 
better understanding of disease pathophysiology, and identify new opportunities for 
prevention and risk stratification. While NSAIDs have been consistently associated with 
reduced risk of esophageal adenocarcinoma, it is unclear whether they may affect risk 
through preventing the development of Barrett's esophagus, by preventing the development 
of esophageal adenocarcinoma in patients with Barrett's esophagus, or both. This question 
has substantial clinical implications, because attempts at chemoprevention with NSAIDs in 
the setting of Barrett's esophagus are only logical if the effect of NSAIDs occurs after the 
Thrift et al. Page 2
Am J Gastroenterol. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
development of Barrett's esophagus. A recent meta-analysis of five studies showed a 30% 
reduction in the risk of progression from Barrett's esophagus to esophageal adenocarcinoma 
among NSAID users, as compared with nonusers (12). In contrast, results from 
epidemiological studies of the association between NSAIDs and the risk of Barrett's 
esophagus have been largely inconclusive, where both negative (13-15) and positive 
associations (16,17) have been reported.
We therefore conducted a large analysis of pooled individual-level data from six case-control 
studies in the BEACON Consortium to comprehensively examine the association between 
use of NSAIDs and the risk of Barrett's esophagus.
METHODS
Study population
We analyzed individual-level participant data from six population-based case-control studies 
in BEACON that had available data on NSAID use (Supplementary Table 1). The six studies 
were as follows: the Houston Barrett's Esophagus study (based at the Michael E. DeBakey 
VA Medical Center at Houston, TX; hereafter “Houston”) (17); the Factors Influencing the 
Barrett's/Adenocarcinoma Relationship study (based in Ireland; “FINBAR”) (13); the 
Epidemiology and Incidence of Barrett's Esophagus study (based in the Kaiser Permanente 
Northern California population; “KPNC”) (14); The Newly Diagnosed Barrett's Esophagus 
Study (based at the University of Michigan and Ann Arbor Veterans Affairs Medical Center 
at Ann Arbor, MI; “NDB”) (18); the Study of Digestive Health (based in Brisbane, 
Australia; “SDH”) (16); and the Study of Reflux Disease (based in western Washington 
State; “SRD”) (19). We additionally restricted our analyses to non-Hispanic white study 
participants due to low numbers of cases from non-white ethnic groups (total n=95; range 
n=17 in NDB to n=43 in KPNC). The Institutional Review Boards or Research Ethics 
Committees of each institution approved the acquisition and pooling of data for the present 
analysis. Participants provided written informed consent to take part in the studies.
In all studies, cases included persons with endoscopic evidence of columnar mucosa in the 
tubular esophagus, accompanied by the presence of specialized intestinal metaplasia in an 
esophageal biopsy, and cases included persons with prevalent and newly diagnosed Barrett's 
esophagus (Supplementary Table 1). The SRD also included some patients with specialized 
intestinal esophageal metaplasia on biopsy, but without endoscopically visible columnar 
metaplasia. The NDB study included only males (cases and controls) (18).
The cases were compared separately with (1) population-based controls, representing the 
underlying source population from which cases arose, and (2) gastroesophageal reflux 
disease (GERD) controls, representing the population undergoing endoscopy from which 
cases are diagnosed.
Study variables
Data for medication use was self-reported in all studies (Supplementary Table 1). Five of the 
six studies asked about “regular use” of medications over a specified time period with a 
minimum frequency of use (13,14,17-19). The duration of regular use varied across the five 
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studies, from 3 months to 1 year of use. The definition for frequency of regular use was 
consistent across the five studies, each specified as at least once per week. The remaining 
study did not define regular use; for this study we reclassified study participants as regular 
users if their reported frequency of use was at least once per week (16).
The main exposure categories used in the analysis were regular (at least once per week) use 
of the medication (aspirin, non-aspirin NSAIDs, any NSAIDs) and non-regular use (referent 
group; less than once per week use for each category). Medication use was further classified 
by frequency (weekly—<daily and at least daily) and duration (< 5 years and ≥ 5 years) of 
use.
Potential confounding variables were available from all studies as part of a core dataset and 
were harmonized by the coordinating center. Variables that were selected a priori as 
adjustment factors included age (<50, 50−<60, 60−<70, ≥70 years), sex (except for NDB 
which included only males), highest level of education (school only, tech/diploma, 
university), smoking status (never, former, current) and body mass index (BMI; <25, 
25-29.9, ≥30 kg/m2). Models that compared cases with population-based controls were also 
subsequently adjusted for self-reported GERD symptoms (less than weekly vs. at least 
weekly) to evaluate potential confounding effects of GERD symptoms. Frequency of GERD 
symptoms was defined as the highest reported frequency of either heartburn or acid 
regurgitation symptoms; “frequent symptoms” were those occurring at least weekly.
Statistical analysis
We used multivariable logistic regression to estimate study-specific ORs and 95% CIs for 
the association between NSAID use and risk of Barrett's esophagus. The study-specific ORs 
were then combined using random-effects meta-analytic models to generate a summary OR. 
We used the inconsistency index, I2, and its 95% uncertainty interval (UI) to assess 
heterogeneity between studies (20). Larger I2 values reflect increasing heterogeneity, beyond 
what is attributable to chance. I2 values of 25%, 50% and 75% were used as evidence of low, 
moderate, or high levels of heterogeneity, respectively. A leave-one-out sensitivity analysis 
was performed by iteratively removing one study at a time to assess whether a single study 
was contributing to high (if present) between-study heterogeneity and to confirm that our 
findings were not driven by any single study (21). For comparisons with population-based 
controls only, we assessed whether the association between NSAID use and the risk of 
Barrett's esophagus was modified by frequency of GERD symptoms (less than weekly, at 
least weekly) by performing likelihood ratio tests of nested models with and without the 
NSAID-GERD interaction term.
All tests for statistical significance were two-sided at α=0.05 and analyses were conducted 
using Stata 13.1 (StataCorp LP, College Station, TX).
RESULTS
We included data from 1474 cases, 2256 population-based controls and 2018 GERD 
controls in the analysis. In total, 31.7% of the study population reported regular (at least 
once weekly) use of aspirin, 19.6% reported regular use of non-aspirin NSAIDs, and 47.0% 
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reported regular use of any NSAIDs. However, the prevalence of use among controls (and 
cases) varied considerably across the six studies (Supplementary Table 2). For example, 
prevalence of prior regular use of aspirin in population-based controls ranged from 10.7% in 
SDH to 47.3% in NDB; in cases, from 17.0% in SDH to 49.6% in NDB.
Aspirin
Figure 1A shows the association between aspirin use and risk of Barrett's esophagus. In the 
multivariable analysis, there was no association between prior regular use of aspirin (fully 
adjusted OR = 1.00, 95% CI = 0.76–1.32) and the risk of Barrett's esophagus for comparison 
with population-based controls (Table 1). We found moderate between-study heterogeneity 
(I2=56%), but with a wide uncertainty interval (95% UI = 0%–82%). Among five studies 
that reported information on frequency of use (SDH did not capture daily medication use), 
prior daily use of any aspirin was not associated with the risk of Barrett's esophagus (fully 
adjusted OR = 0.93, 95% CI = 0.71–1.21), with no evidence of between-study heterogeneity 
(I2=10%). With regard to duration of use (Table 1), we found no association between 
duration of prior aspirin use and risk of Barrett's esophagus (fully adjusted OR for ≥ 5 years 
= 1.04, 95% CI = 0.70–1.54; I2=59%). We found similar null findings for aspirin use when 
we compared cases with GERD controls (Table 2) and in analyses (cases vs. population-
based controls) stratified by frequency of GERD symptoms (Table 3).
Non-aspirin NSAIDs
When compared with population-based controls, regular use of any non-aspirin NSAIDs was 
not associated with the risk of Barrett's esophagus (fully adjusted OR = 1.16, 0.86–1.56; 
I2=49%) (Figure 1B). We found no evidence of effect modification by frequency of GERD 
symptoms (Table 3). Among the five studies that reported information on frequency and 
duration of use, we found some evidence for a modest increased risk of Barrett's esophagus 
associated with prior daily use of any non-aspirin NSAIDs (fully adjusted OR = 1.42, 95% 
CI = 0.92–2.18; I2=37%) and ≥ 5 years of non-aspirin NSAID use (fully adjusted OR = 1.57, 
95% CI = 1.09–2.26; I2=7%). However, there were no associations between frequency and 
duration of non-aspirin NSAID use and the risk of Barrett's esophagus for comparisons with 
GERD controls (Table 2).
Any NSAIDs
Using data from the six studies, there was no association between regular use of any 
NSAIDs (adjusted OR = 1.00, 0.76–1.32; I2=61%) and the risk of Barrett's esophagus for 
comparison with population-based controls (Table 1). There was no association between 
daily use of any NSAIDs and Barrett's esophagus (fully adjusted OR = 1.01, 95% CI = 0.69–
1.47; I2=57%). With regard to duration of use (Table 1), we found no association between 
duration of prior NSAID use and risk of Barrett's esophagus (fully adjusted OR for ≥ 5 years 
= 1.05, 95% CI = 0.67–1.64; I2=71%). We found similar null findings when we compared 
cases with GERD controls (Table 2) and in analyses (cases vs. population-based controls) 
stratified by frequency of GERD symptoms (Table 3).
While there was evidence of between-study heterogeneity for associations between NSAID 
use and the risk of Barrett's esophagus, the results remained unchanged in the leave-one-out 
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analysis (Supplementary Table 3), indicating that our results were not driven by any single 
study.
DISCUSSION
To our knowledge, this pooled analysis is the largest evaluation of NSAID use and risk of 
Barrett's esophagus to date. It included six well-characterized population-based case-control 
studies with similar assessments of regular medication use. We observed no overall 
association between regular use of any NSAIDs, as well as for the individual effects of 
aspirin and non-aspirin NSAIDs, and the risk of Barrett's esophagus. Furthermore, we found 
no evidence of an inverse relationship between increased frequency or duration of NSAID 
use and the risk of Barrett's esophagus. We did observe a moderate level of heterogeneity 
among the studies for many of the effect estimates, but with wide uncertainty intervals, and 
the associations with NSAID use remained non-significant when individual studies were 
omitted following “leave-one-out” analyses.
There is consistent evidence from epidemiological studies for an inverse relationship 
between use of NSAIDs and the risk of esophageal adenocarcinoma. In the largest study to 
date, pooled analyses of data from BEACON showed greater than 30% reduction in the risk 
of esophageal adenocarcinoma among NSAID users, as compared with nonusers (4). The 
association between NSAID use and esophageal adenocarcinoma was especially strong 
among daily users (adjusted OR = 0.56, 95% CI = 0.43–0.73; I2=0%). However, there 
remained considerable uncertainty regarding the stage(s) of neoplastic progression in which 
NSAIDs may act, whether in preventing the development of Barrett's esophagus, preventing 
progression to esophageal adenocarcinoma in patients with Barrett's esophagus, or both.
Several well designed prospective and retrospective studies have examined the association 
between NSAID use and risk of progression from Barrett's esophagus to esophageal 
adenocarcinoma. In their recent meta-analysis examining the association with NSAID use, 
Zhang et al. (12) showed a 30% reduction in the risk of esophageal adenocarcinoma among 
patients with Barrett's esophagus (adjusted OR = 0.70, 95% CI = 0.52–0.95) with minimal 
heterogeneity between the five studies (I2 = 28%). They found no significant differences in 
the magnitude in the association with aspirin use or non-aspirin NSAID use and the 
association was independent of duration of use.
While several observational studies have assessed the association between NSAID use and 
the risk of Barrett's esophagus, the results have been inconclusive. The reasons for the 
contrasting results are not clear and differences in populations and methods make direct 
comparisons between published studies difficult. We attempted to overcome some of these 
shortcomings by using harmonized data from multiple well-conducted case-control studies 
and meta-analytic methods. Regardless, we observed a wide range of results for each of the 
studies included in this analysis, with results from FINBAR and SRD at the opposite 
extremes. The studies in BEACON were conducted in different countries, over different time 
periods (from 1997 to 2013), and used different questionnaires for ascertainment of 
medication use; all of which could have contributed to these differences in reported effect 
sizes. Along these lines, it is worth noting that self-reported prevalence of NSAID use 
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among population controls varied from 20% in SDH to over 60% in NDB and the Houston 
study. However, in a series of sensitivity analyses (based on study period, recent vs. lifetime 
use) and in the leave-one-out analysis, the null findings were essentially unchanged.
Intriguingly, while we consistently found no association with aspirin use, we observed some 
evidence for higher risk of Barrett's esophagus associated with both daily use and use greater 
than 5 years of non-aspirin NSAIDs. It is not clear why there would be a difference in 
associations with non-aspirin NSAIDs and aspirin; it is possible that there may be some kind 
of interplay between prostaglandins, which causes inflammation, changes in DNA, and 
increased carcinogenesis. Alternatively, the non-aspirin NSAID association may in part be 
due to alternate prescribing trends for the cases (who are more likely to have GERD 
symptoms and be obese), taking non-aspirin NSAIDs as a substitute for aspirin because they 
are milder on the stomach.
It is biologically plausible that NSAID use may reduce risk of neoplastic progression in 
patients with Barrett's esophagus. NSAID use is associated with a reduction in the risk of 
other gastrointestinal cancers, and also reduces the rate of cancer progression in 
precancerous lesions. These effects are postulated to occur by inhibiting cyclooxygenase-2 
(COX-2) enzyme production and retarding tumor growth promoted by prostaglandins 
(22,23). Studies have shown elevated COX-2 expression in Barrett's esophagus, and also 
increased COX-2 expression associated with neoplastic progression from Barrett's 
esophagus to esophageal adenocarcinoma (24,25). Furthermore, experimental studies have 
found that treating Barrett's esophagus cells with COX-2 inhibitors can inhibit cell growth 
(26,27). However, data are limited in humans and we await the results of the ASPECT trial 
which randomized patients with Barrett's esophagus to aspirin and proton pump inhibitors 
with a view to inhibiting cancer (28).
The results from our study have implications for chemoprevention. If NSAIDs stopped the 
development of Barrett's esophagus, the target group for treatment would be 40% of the 
population to decrease a fraction of the 10,000 esophageal adenocarcinoma cases in the U.S. 
every year. Given that NSAIDs are not benign, it is unlikely that such an effort is either 
worthwhile or feasible. If, on the other hand, NSAIDs work after the development of 
Barrett's esophagus, we have a more reasonable strategy whereby we treat a much smaller 
group of patients at much higher risk to achieve chemoprevention.
This large pooled analysis of individual-level participant data from six case-control studies 
in BEACON offered several notable strengths. With almost 1500 cases of Barrett's 
esophagus, we had greater power to detect associations, if present, than in any of the 
previous single site studies. Furthermore, because we were able to evaluate NSAID exposure 
compared with a common reference group (non-regular use), we reduced the potential for 
exposure misclassification. While we observed moderate heterogeneity across studies, we 
found no evidence that any individual study was overly influential, thus providing additional 
robustness and confidence to our findings. Finally, the use of individual-level data, with 
variables standardized across studies, and the ability to control for a wide range of potential 
confounders collected consistently across the studies were additional strengths of this pooled 
analysis.
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Our study also has a number of limitations. There was some variability among the exposure 
questions from different studies; in particular, the definition of regular use. We addressed the 
misclassification of exposure definition across the studies by using a standard definition for 
regular use as described in the Methods; in the one study that did not specify regular use 
(16), we reclassified participants accordingly. Because of the way in which the individual 
studies asked participants about medication use (e.g., “have you used NSAIDs at least 
weekly in the past year?”), we were unable to examine separately ‘no use’ versus ‘low use’ 
of NSAIDs. The individual study ORs may differ somewhat from the pooled ORs due to 
differences in confounding structure. For example, race was a strong confounder of the 
association between NSAID use and risk of Barrett's esophagus in KPNC (14). Here, we 
limited the analyses to non-Hispanic white study participants. Finally, most of the six studies 
included a mix of patients with newly diagnosed and prevalent diagnoses of Barrett's 
esophagus, which could have biased the results unpredictably.
In summary, this pooled analysis found no evidence for an inverse association between use 
of NSAIDs and the risk of Barrett's esophagus. Given the known inverse association 
between NSAIDs and the risk of esophageal adenocarcinoma, and analogous to that 
observed for colon cancer and polyps whereby NSAID use may stop progression from pre-
cancer to cancer, these findings support investigations into the use of these chemopreventive 
agents for decreasing the risk of neoplastic progression from Barrett's esophagus to 
esophageal adenocarcinoma.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• Epidemiological studies have consistently shown an inverse association 
between regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) 
and risk of esophageal adenocarcinoma.
• However, it remains unclear whether use of NSAIDs is also inversely 
associated with the precursor lesion, Barrett's esophagus.
WHAT IS NEW HERE
• Use of NSAIDs was not associated with a reduced risk of Barrett's 
esophagus.
• The findings from this large pooled analysis suggest that the likely 
protective mechanism of NSAIDs on esophageal adenocarcinoma 
occurs after to the development of Barrett's esophagus.
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Figure 1. Associations between NSAID use and risk of Barrett's esophagus
The summary odds ratios and 95% confidence intervals (CI) for the association between 
Barrett's esophagus and A) at least weekly aspirin use; B) at least weekly non-aspirin 
NSAID use; and C) at least weekly use of any NSAIDs. Summary odds ratios and 95% 
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confidence intervals were estimated using a random-effects meta-analytic model. All 
statistical tests were two-sided. % Weight describes the weighting each study contributes to 
the summary odds ratio. The dot on each square represents the study-specific odds ratio, and 
the size of the surrounding square is an illustrative representation of study weighting. The 
horizontal lines represent the confidence intervals; if ending in an arrow, this indicates that 
the interval transcends the region plotted. The diamond represents the summary odds ratio 
and 95% confidence intervals. Houston = the Houston Barrett's Esophagus study; FINBAR = 
Factors Influencing the Barrett's Adenocarcinoma Relationship Study; KPNC = the 
Epidemiology and Incidence of Barrett's Esophagus study; NDB = The Newly Diagnosed 
Barrett's Esophagus Study; SDH = the Study of Digestive Health; SRD = the Study of 
Reflux Disease.
Thrift et al. Page 13
Am J Gastroenterol. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thrift et al. Page 14
Ta
bl
e 
1
O
dd
s R
at
io
s a
nd
 9
5%
 C
on
fid
en
ce
 In
te
rv
al
s f
or
 th
e 
A
ss
oc
ia
tio
n 
Be
tw
ee
n 
Fr
eq
ue
nc
y 
of
 N
on
-s
te
ro
id
al
 A
nt
i-i
nf
la
m
m
at
or
y 
D
ru
g 
U
se
 a
nd
 R
isk
 o
f B
ar
re
tt'
s 
Es
op
ha
gu
s C
om
pa
re
d 
w
ith
 P
op
ul
at
io
n-
ba
se
d 
Co
nt
ro
ls
N
o.
 o
f s
tu
di
es
O
R
 (9
5%
 C
I)
I2
 
(95
%
 U
I)
O
R
a
 
(95
%
 C
I)
I2
 
(95
%
 U
I)
O
R
b  
(95
%
 C
I)
I2
 
(95
%
 U
I)
A
sp
iri
n 
us
e
 
 
 
 
N
on
us
er
 (<
 w
ee
kly
 us
e)
1.
00
1.
00
1.
00
 
 
 
 
A
t l
ea
st 
w
ee
kl
y
6
1.
09
 (0
.84
-1.
43
)
66
 (1
8-8
7)
1.
02
 (0
.80
-1.
29
)
50
 (0
-80
)
1.
00
 (0
.76
-1.
32
)
56
 (0
-82
)
 
 
 
 
 
 
 
 
W
ee
kl
y-
<d
ai
ly
5
1.
11
 (0
.78
-1.
56
)
14
 (0
-82
)
1.
02
 (0
.73
-1.
42
)
8 
(0-
81
)
0.
88
 (0
.62
-1.
26
)
6 
(0-
80
)
 
 
 
 
 
 
 
 
A
t l
ea
st 
da
ily
5
0.
96
 (0
.74
-1.
26
)
35
 (0
-76
)
0.
90
 (0
.72
-1.
13
)
2 
(0-
80
)
0.
93
 (0
.71
-1.
21
)
10
 (0
-81
)
 
 
 
 
D
ur
at
io
n 
of
 u
se
 
 
 
 
 
 
 
 
<
5 
ye
ar
s
5
0.
93
 (0
.74
-1.
17
)
0 
(0-
34
)
0.
85
 (0
.67
-1.
09
)
0 
(0-
40
)
0.
81
 (0
.62
-1.
06
)
0 
(0-
67
)
 
 
 
 
 
 
 
 
≥5
 y
ea
rs
5
1.
09
 (0
.76
-1.
57
)
64
 (6
-86
)
1.
05
 (0
.71
-1.
55
)
65
 (7
-87
)
1.
04
 (0
.70
-1.
54
)
59
 (0
-85
)
N
on
-a
sp
iri
n 
N
SA
ID
 u
se
 
 
 
 
N
on
us
er
 (<
 w
ee
kly
 us
e)
1.
00
1.
00
1.
00
 
 
 
 
A
t l
ea
st 
w
ee
kl
y
6
1.
34
 (1
.01
-1.
78
)
58
 (0
-83
)
1.
20
 (0
.89
-1.
62
)
57
 (0
-83
)
1.
16
 (0
.86
-1.
56
)
49
 (0
-80
)
 
 
 
 
 
 
 
 
W
ee
kl
y-
<d
ai
ly
5
1.
18
 (0
.63
-2.
23
)
68
 (1
8-8
8)
0.
99
 (0
.50
-1.
98
)
70
 (2
2-8
8)
0.
97
 (0
.50
-1.
89
)
64
 (4
-86
)
 
 
 
 
 
 
 
 
A
t l
ea
st 
da
ily
5
1.
51
 (1
.04
-2.
21
)
39
 (0
-78
)
1.
42
 (0
.95
-2.
12
)
41
 (0
-78
)
1.
42
 (0
.92
-2.
18
)
37
 (0
-76
)
 
 
 
 
D
ur
at
io
n 
of
 u
se
 
 
 
 
 
 
 
 
<
5 
ye
ar
s
5
1.
13
 (0
.81
-1.
57
)
34
 (0
-75
)
1.
04
 (0
.79
-1.
36
)
0 
(0-
79
)
1.
02
 (0
.77
-1.
37
)
0 
(0-
78
)
 
 
 
 
 
 
 
 
≥5
 y
ea
rs
5
1.
76
 (1
.27
-2.
43
)
9 
(0-
81
)
1.
63
 (1
.10
-2.
43
)
28
 (0
-72
)
1.
57
 (1
.09
-2.
26
)
7 
(0-
81
)
A
ny
 N
SA
ID
 u
se
 
 
 
 
N
on
us
er
 (<
 w
ee
kly
 us
e)
1.
00
1.
00
1.
00
 
 
 
 
A
t l
ea
st 
w
ee
kl
y
6
1.
14
 (0
.85
-1.
53
)
74
 (4
1-8
7)
1.
04
 (0
.81
-1.
34
)
61
 (4
-84
)
1.
00
 (0
.76
-1.
32
)
61
 (4
-84
)
 
 
 
 
 
 
 
 
W
ee
kl
y-
<d
ai
ly
5
1.
05
 (0
.64
-1.
72
)
64
 (5
-86
)
0.
92
 (0
.55
-1.
56
)
65
 (8
-87
)
0.
84
 (0
.49
-1.
42
)
59
 (0
-85
)
 
 
 
 
 
 
 
 
A
t l
ea
st 
da
ily
5
1.
14
 (0
.78
-1.
66
)
70
 (2
3-8
8)
1.
04
 (0
.74
-1.
46
)
58
 (0
-84
)
1.
01
 (0
.69
-1.
47
)
57
 (0
-84
)
 
 
 
 
D
ur
at
io
n 
of
 u
se
 
 
 
 
 
 
 
 
<
5 
ye
ar
s
5
0.
92
 (0
.74
-1.
14
)
0 
(0-
71
)
0.
84
 (0
.67
-1.
06
)
0 
(0-
46
)
0.
80
 (0
.62
-1.
03
)
0 
(0-
70
)
 
 
 
 
 
 
 
 
≥5
 y
ea
rs
5
1.
17
 (0
.74
-1.
84
)
80
 (5
2-9
1)
1.
10
 (0
.69
-1.
73
)
77
 (4
4-9
1)
1.
05
 (0
.67
-1.
64
)
71
 (2
6-8
9)
a M
od
el
s i
nc
lu
de
d 
te
rm
s f
or
 a
ge
 (<
50
, 5
0-5
9, 
60
-69
, ≥
70
 ye
ars
), s
ex
 (e
x
ce
pt
 N
D
B,
 a
ll 
m
al
e),
 ed
uc
ati
on
 (s
ch
oo
l o
nly
,
 
te
ch
/d
ip
lo
m
a,
 u
ni
v
er
sit
y),
 sm
ok
ing
 st
atu
s (
ne
v
er
,
 
fo
rm
er
,
 
cu
rr
en
t) 
an
d b
od
y m
ass
 in
de
x
 
(<
25
, 2
5-2
9.9
, ≥
30
 kg
/m
2 )
.
b M
od
el
s a
dju
ste
d f
or 
sam
e f
ac
to
rs
 a
s 
(a)
 bu
t a
lso
 G
ER
D
 sy
m
pt
om
s (
les
s t
ha
n w
ee
kly
,
 
at
 le
as
t w
ee
kl
y).
Am J Gastroenterol. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thrift et al. Page 15
Ta
bl
e 
2
O
dd
s R
at
io
s a
nd
 9
5%
 C
on
fid
en
ce
 In
te
rv
al
s f
or
 th
e 
A
ss
oc
ia
tio
n 
Be
tw
ee
n 
Fr
eq
ue
nc
y 
of
 N
on
-s
te
ro
id
al
 A
nt
i-i
nf
la
m
m
at
or
y 
D
ru
g 
U
se
 a
nd
 R
isk
 o
f B
ar
re
tt'
s 
Es
op
ha
gu
s C
om
pa
re
d 
w
ith
 G
ER
D
 C
on
tro
ls
N
o.
 o
f s
tu
di
es
O
R
 (9
5%
 C
I)
I2
 
(95
%
 U
I)
O
R
a
 
(95
%
 C
I)
I2
 
(95
%
 U
I)
A
sp
iri
n 
us
e
 
 
 
 
N
on
us
er
 (<
 w
ee
kly
 us
e)
1.
00
1.
00
 
 
 
 
A
t l
ea
st 
w
ee
kl
y
5
1.
18
 (0
.92
-1.
52
)
57
 (0
-84
)
1.
04
 (0
.82
-1.
30
)
40
 (0
-78
)
 
 
 
 
 
 
 
 
W
ee
kl
y-
<d
ai
ly
4
1.
17
 (0
.83
-1.
64
)
13
 (0
-87
)
1.
06
 (0
.78
-1.
46
)
2 
(0-
85
)
 
 
 
 
 
 
 
 
A
t l
ea
st 
da
ily
4
0.
97
 (0
.61
-1.
54
)
72
 (2
1-9
0)
0.
83
 (0
.51
-1.
33
)
69
 (1
1-8
9)
 
 
 
 
D
ur
at
io
n 
of
 u
se
 
 
 
 
 
 
 
 
<
5 
ye
ar
s
4
0.
98
 (0
.61
-1.
58
)
74
 (2
6-9
1)
0.
89
 (0
.53
-1.
48
)
75
 (3
0-9
1)
 
 
 
 
 
 
 
 
≥5
 y
ea
rs
4
1.
27
 (1
.02
-1.
59
)
0 
(0-
78
)
1.
14
 (0
.90
-1.
45
)
0 
(0-
73
)
N
on
-a
sp
iri
n 
N
SA
ID
 u
se
 
 
 
 
N
on
us
er
 (<
 w
ee
kly
 us
e)
1.
00
1.
00
 
 
 
 
A
t l
ea
st 
w
ee
kl
y
5
0.
92
 (0
.69
-1.
23
)
51
 (0
-82
)
0.
94
 (0
.76
-1.
16
)
3 
(0-
80
)
 
 
 
 
 
 
 
 
W
ee
kl
y-
<d
ai
ly
4
0.
85
 (0
.62
-1.
15
)
0 
(0-
82
)
0.
85
 (0
.62
-1.
18
)
0 
(0-
80
)
 
 
 
 
 
 
 
 
A
t l
ea
st 
da
ily
4
0.
89
 (0
.56
-1.
43
)
54
 (0
-85
)
0.
93
 (0
.62
-1.
39
)
32
 (0
-76
)
 
 
 
 
D
ur
at
io
n 
of
 u
se
 
 
 
 
 
 
 
 
<
5 
ye
ar
s
4
0.
83
 (0
.58
-1.
17
)
30
 (0
-74
)
0.
84
 (0
.62
-1.
13
)
0 
(0-
83
)
 
 
 
 
 
 
 
 
≥5
 y
ea
rs
4
0.
97
 (0
.71
-1.
32
)
0 
(0-
64
)
1.
00
 (0
.72
-1.
38
)
0 
(0-
73
)
A
ny
 N
SA
ID
 u
se
 
 
 
 
N
on
us
er
 (<
 w
ee
kly
 us
e)
1.
00
1.
00
 
 
 
 
A
t l
ea
st 
w
ee
kl
y
5
1.
07
 (0
.86
-1.
34
)
52
 (0
-82
)
0.
99
 (0
.82
-1.
19
)
19
 (0
-83
)
 
 
 
 
 
 
 
 
W
ee
kl
y-
<d
ai
ly
4
1.
05
 (0
.81
-1.
36
)
0 
(0-
39
)
1.
00
 (0
.76
-1.
31
)
0 
(0-
17
)
 
 
 
 
 
 
 
 
A
t l
ea
st 
da
ily
4
0.
99
 (0
.71
-1.
38
)
59
 (0
-86
)
0.
90
 (0
.68
-1.
20
)
37
 (0
-78
)
 
 
 
 
D
ur
at
io
n 
of
 u
se
 
 
 
 
 
 
 
 
<
5 
ye
ar
s
4
0.
84
 (0
.62
-1.
14
)
44
 (0
-81
)
0.
79
 (0
.56
-1.
10
)
48
 (0
-83
)
 
 
 
 
 
 
 
 
≥5
 y
ea
rs
4
1.
12
 (0
.90
-1.
39
)
0 
(0-
74
)
1.
03
 (0
.82
-1.
29
)
0 
(0-
57
)
a M
od
el
s i
nc
lu
de
d 
te
rm
s f
or
 a
ge
 (<
50
, 5
0-5
9, 
60
-69
, ≥
70
 ye
ars
), s
ex
 (e
x
ce
pt
 N
D
B,
 a
ll 
m
al
e),
 ed
uc
ati
on
 (s
ch
oo
l o
nly
,
 
te
ch
/d
ip
lo
m
a,
 u
ni
v
er
sit
y),
 sm
ok
ing
 st
atu
s (
ne
v
er
,
 
fo
rm
er
,
 
cu
rr
en
t) 
an
d b
od
y m
ass
 in
de
x
 
(<
25
, 2
5-2
9.9
, ≥
30
 kg
/m
2 )
.
Am J Gastroenterol. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thrift et al. Page 16
Table 3
Adjusted Odds Ratios and 95% Confidence Intervals for the Association Between Frequency of Non-steroidal 
Anti-inflammatory Drug Use and Risk of Barrett's Esophagus Compared with Population-based Controls, 
Stratified by GERD Symptoms
No. of studies OR (95% CI) I2 (95% UI)
Less than weekly GERD symptoms
    Aspirin use
        Nonuser (< weekly use) 1.00
        At least weekly 6 1.06 (0.66-1.70) 40 (0-76)
    Non-aspirin NSAID use
        Nonuser (< weekly use) 1.00
        At least weekly 6 1.13 (0.47-2.71) 61 (6-84)
    Any NSAID use
        Nonuser (< weekly use) 1.00
        At least weekly 6 0.94 (0.53-1.65) 57 (0-83)
At least weekly GERD symptoms
    Aspirin use
        Nonuser (< weekly use) 1.00
        At least weekly 6 0.98 (0.73-1.32) 36 (0-74)
    Non-aspirin NSAID use
        Nonuser (< weekly use) 1.00
        At least weekly 6 1.30 (0.99-1.70) 16 (0-79)
    Any NSAID use
        Nonuser (< weekly use) 1.00
        At least weekly 6 1.12 (0.88-1.42) 17 (0-62)
Models included terms for age (<50, 50-59, 60-69, ≥70 years), sex (except NDB, all male), education (school only, tech/diploma, university), 
smoking status (never, former, current), and body mass index (<25, 25-29.9, ≥30 kg/m2)
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